Natriuretic peptides (NPs) are essential for the maintenance of volume homeostasis, and can be of myocardial, renal, and endothelial origin. Advances in peptide engineering have enabled the design of innovative designer NPs that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Therefore, designer NPs provide an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the NPs that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension. (J Am Coll Cardiol Basic Trans Science 2016;1:557-67)
pGC-B receptors are expressed in kidney, brain and veins, but less so in arteries (17) .
A third NPR, called NPR-C, or the clearance receptor (18), actively eliminates endogenous NPs from the circulation using hydrolysis (ranked from the greatest to the lowest degradation rate: VNP ¼ ANP $ CNP > BNP ¼ DNP). Studies also suggest a signaling role for NPR-C via modulation of cyclic adenosine monophosphate (19) (20) (21) . Clearance of NPs is furthermore regulated by the enzyme NEP, which is widely expressed in endothelium and lung with the highest abundance in the kidney. CNP is the least resistant to NEP-mediated hydrolysis (ranked from greatest to lowest degradation rate: CNP > ANP > BNP > DNP) (3, 10, 15, 16) . The differences in local NPR expression, degradation and clearance rates, and NP-binding affinity cause all 6 NPs to have unique and NP-specific properties (15) .
Importantly, binding of a NP to a NPR activates the membrane-bound pGC-A and pGC-B receptors, and induces a variety of autocrine, paracrine, and endocrine effects. Activated pGC receptors produce the second messenger cyclic guanosine monophosphate (cGMP) that in turn activates protein kinase G. cGMP can also be produced in a nitric oxide-dependent manner; its production is then regulated via activation of the soluble guanylyl cyclase pathway (22) .
ANP and BNP are believed to be the most important in controlling body fluid and blood pressure homeostasis (23, 24) . ANP has renin-inhibiting properties, is a potent aldosterone inhibitor, and is an antagonist to the mineralocorticoid receptor. In addition, via alternative processing of the ANP precursor (pro-ANP) it also contributes to renal sodium and water handling via generation of URO (25) (26) (27) . BNP has been identified as an NP highly relevant to HF, which is due to its natriuretic, renin-angiotensin-aldosterone system (RAAS) inhibitory, vasodilating, and lusitropic properties (28) (29) (30) , as well as its robust performance as a HF diagnostic and prognostic biomarker (31) (32) (33) . CNP is an autocrine and paracrine factor that currently has limited use as a therapeutic for HF, particularly because of its rapid enzymatic degradation and paucity of renal protective actions (29) , although its potent antifibrotic actions provide a therapeutic opportunity (34) . Moyes et al. (21) elegantly demonstrated a role for CNP in vascular homeostasis that may involve binding and activation of NPR-C (21). DNP is a unique NP that has only been isolated from the venom gland of the Green Mamba snake (35) . Its function has not been entirely clarified.
Currently, VNP expression has only been confirmed in the hearts of primitive ray-finned bony fish, in which it is responsible for the maintenance of fluid and salt homeostasis (17) .
Overall, NPs possess a wide variety of properties that are of value in diagnosis, prognosis, and treatment of CV disease, especially HF and HTN. Despite current optimal therapies, the prognosis for HF remains poor, Beyond the acute action of carperitide on relief of symptoms, the PROTECT trial investigated the effect of carperitide on long-term prognosis after acute HF (53) . The PROTECT study enrolled 49 patients who were randomly assigned to a group that received lowdose carperitide (0.01 to 0.05 mg/kg/min) for 72 h or to a standard medical treatment group. During infusion, the cardiac free-fatty acid-binding protein/serum creatinine ratio was reduced, which is consistent with inhibition of myocardial cell membrane damage.
There was no significant difference in serum troponin T and creatinine levels between groups. During the 18-month follow-up, the investigators reported that the incidence of death and rehospitalization were significantly lower with carperitide. These studies therefore demonstrated that low-dose ANP infusion in acute HF improved long-term prognosis. Although the mechanism for long-term beneficial effect of carperitide is not clear, inhibition of the RAAS may be involved.
ULARITIDE. Ularitide is a synthesized version of the endogenous NP URO. Ularitide is a 32-residue ANP that activates cGMP production by binding to the pGC-A receptor (26) . It has a fast track designation for treatment of acute HF from the FDA (54).
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Endogenous URO is believed to be produced by the kidney through local synthesis and/or processing of renal or circulating pro-ANP. URO plays a pivotal role in regulation of urinary sodium excretion. In rats with HF, URO significantly increased urinary flow, glomerular filtration rate (GFR), sodium excretion, and urinary cGMP excretion in a dose-dependent manner (55).
However, in anesthetized dogs with HF that received continuous URO infusion of 2 pmol/kg/min, the increase in urinary sodium excretion was less than in dogs who received BNP infusion (56) . 
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ANX042
Generic name: ASBNP.1
Indication: Cardiorenal syndrome in heart failure Current status: Phase I study of acute intravenous administration in normal human volunteers has been completed.
ZD100
Generic name: MANP Indication: Hypertension Current status: Phase I study of 3-day once daily subcutaneous injection of subjects with resistant-like hypertension has been completed.
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Designer Natriuretic Peptides In human cardiac fibroblasts, CD-NP was furthermore a stronger inhibitor of collagen production than either BNP or CNP (72) . In a model of mild left ventricular diastolic dysfunction with cardiac fibrosis, long-term SQ CD-NP, administered by pump infusion, suppressed the development of both cardiac fibrosis and diastolic dysfunction (71) . Altogether, these and ongoing studies suggest that CD-NP is a unique and
Designer Natriuretic Peptides potent designer NP that has cardiorenal protective properties and antifibrotic actions.
A key strategy in peptide therapeutics is the development of innovative delivery platforms.
In current clinical trials, the OmniPod (Insulet Corporation, Billerica, Massachusetts) insulin delivery system is being used to administer long-term SQ CD-NP in patients with HF. In experimental models of CV disease, novel nanoparticle gel polymer strategies are being tested (74) . Furthermore, a novel film delivery system in which CD-NP is released from a patch-like device around the heart is also being tested (75) . With the advent of highly innovative delivery systems, long-term delivery of CD-NP or designer NPs will continue to emerge. 
